1. Scrip

Finance Watch: Biopharma IPOs Defy Broader Stock Performance Trends

 
• By Mandy Jackson

Public Company Edition: With returns for newly public biopharma companies rising, seven more jumped in line to go public in the US between the beginning of February and early March, while two drug developers launched IPOs in the EU. Meanwhile, already public companies keep raising gobs of cash.

Finance Watch

Since already-good returns for January's initial public offerings are rising, seven additional biopharmaceutical companies indicated their intention to launch IPOs in the US between early February and early March.

January's biopharma IPOs delivered an average return of 52.8% by Feb. 1 and the return for those seven companies grew...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Biopharma Financing Veers Toward Optimism, But Cell And Gene Therapies Left Behind

 
• By Mandy Jackson

While there may be the beginnings of a turnaround in biopharma capital markets, gains in the cell and gene therapy space may lag the broader sector recovery, noted speakers at ARM’s Cell and Gene Meeting on the Mesa.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.

Finance Watch: Job Cuts At Takeda, Bolt, Innate, X4 As Strategies Shift

 
• By Mandy Jackson

Restructuring Edition: Takeda’s shift away from cell therapies will impact 137 employees. Meanwhile, Bolt is cutting its workforce by 50% to extend its cash runway into 2027, Innate’s staffing will drop by 30% and X4 will halve its workforce under a restructuring plan.

India’s R&D Funding Push: Catalytic To De-Risking Early Innovation?

 
• By Anju Ghangurde

India rolls out amended R&D financial assistance plan targeting certain ‘priority areas’ and calls for proposals from industry and startups. While the corpus is modest, the scheme hopes to enable the ‘Innovate in India’ ecosystem and includes a co-funding provision.

More from Business

Ribomic Positions Itself As Latest Potential Achondroplasia Competitor

 
• By Alaric DeArment

The company announced positive Phase II data for umedaptanib pegol and plans to move it into Phase III development in fiscal year 2026.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.

Stock Watch: Baby Steps In Most Favored Nation Drug Pricing

 
• By Andy Smith

Raising UK drug prices and offering lower list prices only to those US patients who are under- or uninsured were the industry’s initially cosmetic answers to the administration’s most favored nation drug pricing challenge. Then Pfizer stepped in.